Despite recent molecular and immunological advancements, prognosis of metastatic
colorectal cancer (mCRC) patients remains poor. In this context, several retrospective and …

Natural killer cells are members of the innate immune system and promote cytotoxic activity
against tumor or infected cells independently from MHC recognition. NK cells are modulated …

Anti-EGFR targeting is one of the key strategies in the treatment of metastatic colorectal
cancer (mCRC). For almost two decades oncologists have struggled to implement EGFR …

Targeted therapy, the milestone in the development of human medicine, originated in 2004
when the FDA approved the first targeted agent bevacizumab for colorectal cancer …

Background The optimal second-line systemic treatment for metastatic colorectal cancer
(mCRC) is inconclusive. Methods We searched PubMed, Web of Science, EMBASE, and …

Interest in the measurement of circulating tumor DNA (ctDNA) in colorectal cancer (CRC)
has increased during the past decade. The analysis of quantitative ctDNA changes as a …

Background The use of targeted drugs and immunotherapy has significantly impacted the
treatment of Colorectal Cancer. However, horizontal comparison among various regimens is …

Background Metastatic colorectal cancer (mCRC) remains a significant clinical challenge.
While anti-EGFR inhibitors have improved survival rates, their long-term efficacy is limited by …

Results: Evaluating baseline, midline, and progression samples, we found that 66.6%
maintained consistent mutational status post-disease progression, while 33.3% exhibited a …

Colorectal cancer (CRC) is one of the most frequent malignancies and, despite screening
programs, it is often diagnosed at late stages. Although current first-and second-line …